Recent

% | $
Quotes you view appear here for quick access.

Microsoft Corporation Message Board

lws2000 4989 posts  |  Last Activity: 5 hours ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The news is so good that $130 is coming very soon. The PE is now very low and will go to 15.

  • I don't see any particular problem with Baidu's current results, or its future plans. Baidu is doing very well now, and they are investing in the future. The stock is not expensive.

    Sentiment: Strong Buy

  • Reply to

    The PE is only TEN

    by georg_washingtn 5 hours ago

    I agree. The forward PE should be around 15.

  • Reply to

    Geron under pressure

    by lws2000 Jul 27, 2015 5:45 PM

    This says it all. Short of fraud at Mayo Clinic (What are the chances of that?), there is no way that this stock will stay down for long, and $5 will be coming soon. The medical information is too good, ODD has been granted, and IMET is unique and needed.

  • lws2000 lws2000 Jul 28, 2015 4:26 PM Flag

    Maine (the old wizard)--When I said "Medical Community" I meant communities, such as Mayo Clinic, the FDA, and JNJ that have intimate knowledge of IMET, and what it is capable of doing. There is no "conjecture" here.

    To give you "your pound of flesh", I am sure that there are some individuals that will "bad mouth" IMET for one reason or another, but, for the most part, they will not be medical reasons based on the data. The negatives are always relative, compared to existing medicines such as JAK or some form of chemo.

    This is a chat room, so each of my statements are based upon my interpretation of data that comes from public forums, including objective reports on this board. There is nothing that I could "prove" to your satisfaction.

  • lws2000 lws2000 Jul 28, 2015 2:16 PM Flag

    I don't know why anyone fights the inevitable upward trend of IMET (as represented by Geron).

  • There are no "nonbelievers" in the medical community. IMET has been proven beyond any doubt (Mayo Clinic original trials --"Tantamount to a Cure" , FDA early approval--ODD; Orphan Drug Designation, JNJ/Janssen's international trials with a direct comparison between IMET (remissions) & JAK (no remissions) coming.

    There are no hurdles or obstacles in the path of JNJ/Janssen (and by association, Geron) from the medical or the scientific community. IMET is effective, safe and unique, and is in the process of getting worldwide recognition and approval. There are no negatives, and huge potentials (blood cancers, all cancers, aging).

  • lws2000 lws2000 Jul 27, 2015 7:19 PM Flag

    I believe this "hit" is temporary. Baidu is investing money in the right technologies, and it is paying off. The potential in China has only been scratched, and Baidu is a global company.

  • Reply to

    Geron under pressure

    by lws2000 Jul 27, 2015 5:45 PM
    lws2000 lws2000 Jul 27, 2015 7:03 PM Flag

    There are no "nonbelievers" in the medical community. IMET has been proven beyond any doubt (Mayo Clinic original trials --"Tantamount to a Cure" , FDA early approval--ODD; Orphan Drug Designation, JNJ/Janssen's international trials with a direct comparison between IMET (remissions) & JAK (no remissions) coming.

  • The volatile markets are not helping Geron, but the PPS has held above $4 in a generally unfriendly market.

  • BEIJING, July 27, 2015 /PRNewswire/ -- Baidu, Inc. the leading Chinese language Internet search provider, today announced its unaudited financial results for the second quarter ended June 30, 2015.

    "With Baidu's cornerstone search business delivering solid growth and enjoying ample runway ahead, and with powerful mobile gateways to leverage, we are ideally positioned to capture the O2O e-commerce opportunity and build the 'Next Baidu'," said Robin Li, chairman and CEO of Baidu. "As we continue to connect people with services and enable closed loop transactions, we are creating a transactional business model as Baidu grows and evolves in the age of mobile."

    "We delivered solid financial results in the second quarter of 2015, with our core search business exhibiting strong growth and attractive profitability," said Jennifer Li, CFO of Baidu. "With the solid base of our core search business, coupled with upward momentum of our O2O e-commerce initiatives, we continue to invest decisively in the 'Next Baidu'. We are delighted by the progress we have achieved and are confident that these investments will generate long term shareholder value. Going forward, we will report the financial impact of the new initiatives, namely O2O & Other[2] and iQiyi."

    Second Quarter 2015 Operational Highlights
    •Mobile search monthly active users (MAUs) were 629 million for the month of June 2015, an increase of 24% year-over-year
    •Mobile maps MAUs were 304 million for the month of June 2015, an increase of 48% year-over-year
    •Gross merchandise value[3] (GMV) for O2O services totaled RMB40.5 billion ($6.5 billion) for the second quarter of 2015, an increase of 109% year-over-year

    Second Quarter 2015 Results
    Baidu reported total revenues of RMB16.575 billion ($2.673 billion) for the second quarter of 2015, representing a 38.3% increase from the corresponding period in 2014.

  • Reply to

    Real chances of getting to $3

    by eejjww36 Jul 22, 2015 1:52 PM
    lws2000 lws2000 Jul 26, 2015 11:37 AM Flag

    We know that the market's cannot be timed, but it seemed that the bottom is close. The question is the demand for the base metals (zinc, copper, etc.) and composite steel in the near future. This has to do with demand in the USA and China.

  • lws2000 lws2000 Jul 22, 2015 12:24 PM Flag

    At this late date, it does not seem likely that IMET will fail in any way. IMET, as a blood cancer drug, is safe, effective and unique. It has also passed every known test for fast track and breakthrough therapy.

  • The comparisons between IMET and JAK will be made on two levels; first general symptoms such as spleen size, and second on the number of remissions and partial remissions. The good news about IMET has been continuous and for the most part ignored:

    1. Tantamount to a Cure (Mayo Clinic)
    2. Liver-holds lifted by FDA
    3. JNJ/Janssen, partner
    4. ODD (Orphan Drug Designation) from FDA
    5. 50 or so international trial sites to get worldwide approvals for IMET
    6. Direct comparison coming between IMET & JAK

    The good news is finally being believed by more investors, as the short hedge funds lose steam. These new international trials will answer most outstanding questions about IMET, MF and other blood cancer cousins. They will also continue the study of combination medicines (example AML in Australia).

  • Reply to

    Why is GERN up 3 cents?

    by hairypotter9 Jul 21, 2015 1:37 PM
    lws2000 lws2000 Jul 21, 2015 3:28 PM Flag

    The news has been continuous and for the most part ignored:

    1. Tantamount to a Cure (Mayo Clinic)
    2. Liver-holds lifted by FDA
    3. JNJ/Janssen, partner
    4. ODD (Orphan Drug Designation) from FDA
    5. 50 or so international trial sites to get worldwide approvals for IMET
    6. Direct comparison coming between IMET & JAK

    The news is finally being believed by more investors, as the short hedge funds lose steam.

  • Reply to

    Conspiracy Theorists

    by blackmarango Jul 20, 2015 1:29 PM
    lws2000 lws2000 Jul 20, 2015 4:35 PM Flag

    black--If #4 or #5 actually happened, Geron's stock would go to pennies, and JNJ would be gone. One never knows, but the probabilities appear to be very, very low, with JNJ/Janssen calling the shots. Geron has a window of opportunity that will not last forever. That is why JNJ is in such a hurry to get worldwide, universal approval for IMET.

  • Reply to

    Conspiracy Theorists

    by blackmarango Jul 20, 2015 1:29 PM
    lws2000 lws2000 Jul 20, 2015 4:00 PM Flag

    There are 5 major factors (IMO):

    1. The hedge funds that "play" with small biotech companies still see Geron as vulnerable, and controllable.
    2. Geron is still not trusted by the investment community (hESC's, liver-holds, management, etc.).
    3. Mayo Clinic's, "Tantamount to a Cure" for some, is not generally believed.
    4. JNJ's attempt to repeat Mayo's (faked ?) successes will fail.
    5. IMET will soon be eclipsed by another medicine.

    I believe that all of these reasons will fade into history, but they are still with us in July, 2015.

  • Reply to

    International Trials 24 week duration (IMET &JNJ)

    by lws2000 Jul 18, 2015 11:37 AM
    lws2000 lws2000 Jul 18, 2015 4:04 PM Flag

    IMET has already received a form of approval from the FDA (ODD or Orphan Drug Designation). As I understand it, Janssen now has considerable leeway in where and how it can use IMET. In addition, as far as I can tell, IMET has met every criteria for various breakthrough therapies. Additional approvals from the FDA and similar organizations in other countries should be coming post haste.

  • For those that are not convinced about the safety and efficacy of IMET, please wait to the end of the JNJ trials to make investment decisions. I have decided that Mayo Clinic cannot be wrong about IMET.

  • Reply to

    News on GERN! !!!!! Here we go!!!!

    by jkokao Jul 16, 2015 8:45 AM
    lws2000 lws2000 Jul 18, 2015 9:26 AM Flag

    I think we all agree that JNJ/Janssen is in control of IMET's future. I don't remember the exact preliminary numbers, but, I believe around 80% (MF trials at Mayo Clinic) benefitted in 4 categories (remissions, partial remissions, improvement, stabilization). As has been point out, " without IMET, the patients would be long dead!!!".

    No one (that I am aware of), at this point in time, doubts the safety and efficacy of IMET, which is fully backed by Mayo Clinic and JNJ/Janssen. There is little doubt that JNJ/Janssen will be able to duplicate and improve upon Mayo's successes.

    I don't know if any of the remissions have been elevated to the cure-status (as in Tantamount to a Cure). JNJ/Janssen is going for the whole-ball-of-wax: worldwide approval of IMET for MF and beyond. I suppose the PPS is being held down by possible medical setbacks in these upcoming trials (24 week duration). So far, no one knows of any such setbacks, and confirmation of the Mayo successes is highly probable. This is now a time to wait, listen and observe.

MSFT
46.29+0.95(+2.10%)Jul 29 4:00 PMEDT